NRSN - NeuroSense Therapeutics Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

2.0000

-0.1250

(-5.88%)

At close: 04:00PM EDT

1.9400

-0.06

(-3.00%)

After hours:

06:10PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Slow Stochastic

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	2.1250
Open	2.1600
Bid	1.8600 x 800
Ask	2.0500 x 900
Day's Range	1.9750 - 2.1600
52 Week Range	1.0750 - 4.4700
Volume	154,725
Avg. Volume	68,933

Market Cap	23.6M
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.2900
Earnings Date	Jun 01, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	7.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NRSN

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

PR Newswire
NeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced financial results for the quarter ended March 31, 2023 and provided a business update.
PR Newswire
NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the completion of enrollment in PARADIGM, a multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in people living with amyotrophic lateral sclerosis (ALS). Study participants are dosed for 6 months after being randomized 2:1 to receive PrimeC or placebo, respectively, followed by a 12-month open label extension
PR Newswire
NeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced positive preliminary results from a novel biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Parkinson's disease (PD), the second most common neurodegenerative disorder. This study compared blood samples from 30 healthy individuals to 30 people living with PD by utilizing neuronal deri
PR Newswire
NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided an update from its CEO, Alon Ben-Noon, on the Company's clinical and operational developments during the first quarter of 2023.
PR Newswire
NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has signed a collaboration agreement with Dr. Ghazaleh Sadri-Vakili, MS, PhD and Massachusetts General Hospital's NeuroEpigenetics Lab to explore the neurotherapeutic effects of its lead combination drug, PrimeC, utilizing a novel in vitro model generated from post-mortem ALS brain tissue (synaptoneurosomes (SNs) system).
PR Newswire
NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Vice President of R&D, Dr. Shiran Zimri, will deliver two presentations at the AD/PD™ 2023 Advances in Science & Therapy Conference which takes place March 28 - April 1, 2023 in Gothenburg, Sweden.
PR Newswire
NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2022, as filed with the Securities and Exchange Commission, is available through its website (https://www.neurosense-tx.com), and provided a business update.
PR Newswire
NeuroSense Therapeutics to Participate in BIO-Europe Spring
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its Chief Medical Officer Dr. Ferenc Tracik and VP of Business Development Nedira Salzman-Frenkel will participate in the 17th annual BIO-Europe Spring partnering conference on March 20-22, 2023 in Basel, Switzerland.
PR Newswire
NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 21, 2023, at 11:00 AM PST and Tuesday, March 28, 2023 at 10:00 AM EST. NeuroSense Therapeutics Ltd. welcomes stakeholders, investors, and other individual followers to register and attend these live events.
PR Newswire
NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today released a corporate update video from its Founder and CEO Alon Ben-Noon.
Simply Wall St.
Here's Why We're Watching NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
PR Newswire
NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a clinical-stage drug development company and QuantalX Neuroscience Ltd; the developer of Delphi-MD, a clinically objective neurodiagnostic medical device, announced today a collaboration to improve early diagnosis and treatment of neurodegenerative diseases. The NeuroSense-QuantalX collaboration comes following NeuroSense's recent report on new biomarker data in Alzheimer's disease (AD) and its plans to initiate a Phase 2 AD clinical trial in the fir
PR Newswire
NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Germany's Federal Institute for Drugs and Medical Devices (BfArM) approved the Company's Clinical Trial Application (CTA) to enroll patients in PARADIGM, its Phase 2b study of its lead combination drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS).
PR Newswire
NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that Health Canada approved the commencement of patient enrollment in Canada for the Company's Phase 2b PARADIGM study of its combination therapy PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). Currently, over 50% of patients have been enrolled in PARADIGM with topline results expected in the second half of 2023.
PR Newswire
NeuroSense Therapeutics Reports Positive Final Results from Alzheimer's Biomarker Study
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease (AD). Preliminary results from the study, showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these encouraging preliminary results,
PR Newswire
NeuroSense Announces Third Quarter 2022 Financial Results and Provides Business Update
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2022 and provided a business update.
PR Newswire
NeuroSense Receives Regulatory Approval to Commence Patient Enrollment in Italy for its Phase 2b Trial in ALS
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it has received approval from the Italian Medicines Agency (AIFA) to commence patient enrollment in Italy for PARADIGM, the Company's Phase 2b clinical trial of its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling patients in Israel and recently received clearance from the U.S. Food an
PR Newswire
NeuroSense Receives FDA Clearance of IND for its ALS Phase 2b Study
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) to enroll patients in the U.S. for its Phase 2b PARADIGM study for its lead drug candidate PrimeC in the treatment of amyotrophic lateral sclerosis (ALS). PARADIGM is currently enrolling patients in Israel, and NeuroSense expects to open clinical sites
PR Newswire
NeuroSense Therapeutics to Present at Upcoming Leading Neuroscience Conferences
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in three upcoming conferences.
PR Newswire
NeuroSense Therapeutics to Participate in BIO-Europe Partnering Conference on October 24-26, 2022 in Lepzing, Germany
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its participation in the BIO-Europe® Partnering Conference on October 24-26, 2022 in Lepzing, Germany.
PR Newswire
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today provided a Q3 update and released the video of Founder and CEO Alon Ben-Noon's remarks at the Nasdaq Opening Bell Ceremony on October 13, 2022. View the video here: LINK.
PR Newswire
NeuroSense Therapeutics to Ring Nasdaq Opening Bell and Host The ALS Combination Therapy Summit on October 13, 2022 in New York City
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced its management team will participate in an Opening Bell Ceremony at the Nasdaq Stock Market on Thursday, October 13, 2022. Alon Ben Noon, NeuroSense's CEO and Founder will lead the ceremony alongside the Company's management, collaborators, and advisors. The ceremony will begin at approximately 9:20 a.m. ET and can be viewed live or via replay here: L
PR Newswire
NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced it will participate in Cantor Fitzgerald's Cantor Neurology and Psychiatry Conference scheduled to take place October 6-7, 2022 in San Francisco.
PR Newswire
NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced results from its multi-dose PK study (NCT05436678) of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS). It is expected that these PK data, combined with the current Phase IIb PARADIGM study, will assist NeuroSense in designing a pivotal Phase III trial of PrimeC for the treatment of ALS in alignment with U.S. Foo
PR Newswire
NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced scientific presentations at two upcoming conferences.